Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Experimental Therapeutics

Activities of Sordarins in Murine Histoplasmosis

John R. Graybill, Laura Najvar, Annette Fothergill, Rosie Bocanegra, Federico Gomez de las Heras
John R. Graybill
University of Texas Health Science Center and
Veterans Administration Hospital, San Antonio, Texas, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Najvar
University of Texas Health Science Center and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annette Fothergill
Veterans Administration Hospital, San Antonio, Texas, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosie Bocanegra
University of Texas Health Science Center and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Federico Gomez de las Heras
Glaxo Wellcome SA, Tres Cantos, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.43.7.1716
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Sordarins are new antifungals which inhibit fungal protein synthesis by blocking elongation factor 2. Three compounds were evaluated in a murine model of histoplasmosis. Immune-competent mice were infected intravenously with 106 to 108 CFU of Histoplasma capsulatum yeast cells. Mice were treated either orally with sordarins or fluconazole from day 2 through 8 after infection or intraperitoneally with amphotericin B during the same period. Protection was measured by increased rates of survival for 30 days after infection or reduction of lung or kidney tissue counts 9 days after infection. All three of the antifungal drugs tested were protective compared with controls. Sordarins were effective at doses as low as 2 mg/kg of body weight/day. This novel class of drugs compared favorably with amphotericin B and fluconazole for the treatment of histoplasmosis.

Histoplasmosis has been recognized as a life-threatening opportunistic infection associated with AIDS (9, 10, 12, 14, 16). Treatment with amphotericin B is effective, but toxicity is a significant side effect (10). Treatment with triazoles is also effective, but because antifungal drug action is slower, these drugs are reserved for less critically ill patients (13, 15). There remains an interest in identifying new classes of antifungal drugs that are rapidly acting, potent, and well tolerated. Sordarins have the potential of being such a class of agents. They interfere with protein synthesis in fungi through a novel mechanism of inhibiting protein elongation factor 2 (4-7, 17). Sordarins have been shown to inhibit a variety of fungal pathogens, including Candida species and Pneumocystis carinii (1, 2, 8). In the present studies, we evaluated the activities of three compounds against infection withHistoplasma capsulatum.

MATERIALS AND METHODS

Pathogen. H. capsulatum clinical isolate 93-255 was obtained from the Fungus Testing Laboratory at the University of Texas Health Science Center, San Antonio. The organism was maintained in the yeast phase on Sabouraud’s agar at 37°C for infection of mice. In vitro testing of conidia was performed by the National Committee for Clinical Laboratory Standards macrobroth method but with incubation continued until the control tube showed visible growth and an end point of 80% inhibition could be determined (11).

Antifungals.Three sordarins, GM211676A (GM1), GM237354A (GM2), and GM193663A (GM3), were obtained from Glaxo Wellcome, Tres Cantos, Madrid, Spain, and were prepared by dissolving in water. Fluconazole (Pfizer, New York, N.Y.) was dissolved in 0.3% Noble agar. Amphotericin B (Bristol-Myers Squibb, Wallingford, Conn.) was suspended in sterile water.

Animals.Outbred immune-competent ICR male mice, 25 to 30 g, were obtained from Charles River Laboratories (Boston, Mass.). Prior to infection, H. capsulatum colonies were scraped from the agar, agitated, washed three times in sterile saline, and suspended in sterile saline for infection. Cells were counted in a hemacytometer for an estimate of the inoculum, and the counts were confirmed by serial colony count dilutions in the yeast phase. Inocula are reported as viable cells. Unanesthetized mice were infected intravenously with 106 to 108 CFU.

Treatment.The infection was allowed to become established for 2 days before the mice were randomized for treatment. Groups of mice were treated either by gavage with water (controls), fluconazole at 5 or 10 mg/kg of body weight twice daily, or one of the GM compounds, in doses ranging from 0.06 to 50 mg/kg twice daily, or intraperitoneally with amphotericin B at 0.06, 0.3, 1.25, 2.5, or 5 mg/kg once daily. Drugs were administered in 0.2-ml volumes per dose.

Protection measures and statistics.For survival studies, groups of 10 mice were treated from day 2 through 8 after infection and observed through day 30. The log rank and Wilcoxon tests of life tables were used for comparisons. Because of multiple comparisons, a P value of <0.001 was considered significant for survival studies. For tissue burden studies, groups of 7 mice were treated from day 2 through 8 and sacrificed on day 9 after infection. The lungs and kidneys were harvested by an aseptic technique. The organs were homogenized, and serial 10-fold colony count dilutions were plated on brain heart infusion agar plates supplemented with 10% sheep blood. These were incubated at 37°C for 2 weeks, and yeast cell colonies were counted. Dunnett’s one-tailed t test was used for comparisons of tissue counts, with a P value of <0.05 determining significance.

RESULTS

In vitro, at 7 days of incubation, the drug concentrations to which H. capsulatum was found to be susceptible were <0.1 μg/ml for GM1, GM2, and GM3; 0.125 μg/ml for amphotericin B; and 4 μg/ml for fluconazole.

For each drug, a toxicity study was performed, in which 10 uninfected mice were treated with 50 mg/kg twice daily for 7 days. In the group treated with GM1, 1 mouse died, but the other 9 mice showed no evidence of illness. There was no mortality or apparent illness in the mice treated with the other two drugs. Three studies of survival were done. In the first screening study (Table 1), where high doses of a drug were administered orally twice daily, all three drugs markedly prolonged survival beyond that of controls. In two subsequent studies, two sordarins were compared with amphotericin B and fluconazole (Table 2). In this study, GM2 was highly effective in prolonging survival at doses down to the lowest tested, 2 mg/kg, while GM3 was ineffective at 5 mg/kg and below. However, the inoculum in the GM3 study was much larger than that for GM2.

View this table:
  • View inline
  • View popup
Table 1.

Mean days of survival of mice infected withH. capsulatuma

View this table:
  • View inline
  • View popup
Table 2.

Survival of mice infected intravenously withH. capsulatuma

An additional study was done to measure the tissue burden of H. capsulatum after treatment with GM3. In this study, mice were infected with a relatively small inoculum, 3.4 × 106CFU. The lungs and kidneys were cultured. As shown in Table3, GM3 was effective in reducing cell counts at 5 or 10 mg/kg but not 1.25 mg/kg. The positive control drugs, fluconazole and amphotericin B, were also effective.

View this table:
  • View inline
  • View popup
Table 3.

Lung and kidney tissue burdensa

DISCUSSION

The sordarins are representative of a class of antifungal agents with a target independent of the cell membrane (targeted by polyenes and triazoles) or the cell wall (targeted by pneumocandins). At a lethal infective dose of approximately 106 CFU of inoculum, GM1 was effective in prolonging survival at 50 and 10 mg/kg. At the same infecting dose, GM2 was effective to the lowest dose tested, 2 mg/kg. At the higher infecting dose of 108 CFU, GM3 was effective at 5 mg/kg but not 1.25 mg/kg. These results were confirmed in studies of the reduction of tissue burden, in which GM3 was effective in reducing tissue counts at 5 mg/kg but not 1.25 mg/kg.

In terms of relative potency, amphotericin B administered at doses of >1 mg/kg prolonged survival and reduced tissue counts much more than the other agents. The sordarins were generally active at 5 mg/kg and higher. In contrast, fluconazole was variably effective at 5 and 10 mg/kg. Fluconazole was also fungistatic, with much less effect on kidney and lung tissue burdens than either the sordarins or amphotericin B. These results suggest that the sordarins are quite potent antifungals with excellent activity against H. capsulatum. On a milligram-for-milligram basis, they may be less potent than amphotericin B, but they are more potent than fluconazole. Further, they can be given orally, unlike amphotericin B.

Due to the limited availability of drugs, the present studies were not sufficient to distinguish among the three sordarins or to permit comparison of all three sordarins with amphotericin B and fluconazole. In the absence of a bioassay or high-pressure liquid chromatography assay, we were not able to study the pharmacokinetics of the drugs. However, others have done so and have reported a correlation between the area under the concentration-time curve and a therapeutic benefit in mice (3). The present studies indicate that sordarins are highly effective against H. capsulatum in this murine model and suggest that they may be further evaluated in vivo for antifungal potency and spectrum. The particular compounds studied herein were not highly active against Aspergillus, but other analogues are under development.

ACKNOWLEDGMENT

Glaxo Wellcome supported these studies.

FOOTNOTES

    • Received 30 December 1998.
    • Returned for modification 26 February 1999.
    • Accepted 23 April 1999.
  • Copyright © 1999 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Aliouat E. M.,
    2. Aviles P.,
    3. Dei-Cas E.,
    4. Herreros E.,
    5. Dujardin L.,
    6. Gargallo-Viola D.
    In vitro pharmaodynamic [sic] parameters of sordarin derivatives in comparison with marketed compounds against rat-derived Pneumocystis carinii, abstr. J-15 Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998 454 American Society for Microbiology Washington, D.C
  2. 2.↵
    1. Alvarez M. E.,
    2. Herreros E.,
    3. Sanchez-Sousa A.,
    4. Gargallo-Viola D.,
    5. Baquero F.
    In vitro activity of sordarins in combination with other systemic antifungal agents against Candida albicans,Aspergillus spp., and Scedosporium apiospermun [sic], abstr. J-12 Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998 454 American Society for Microbiology Washington, D.C
  3. 3.↵
    1. Aviles P.,
    2. Falcoz C.,
    3. Efthymiopoulos C.,
    4. San Roman R.,
    5. Martinez A.,
    6. Jimenez E.,
    7. Marriott M. S.,
    8. Bye A.,
    9. Gomez De Las Heras F.,
    10. Gargallo-Viola D.
    Pharmacokinetic/pharmacodynamic (PK/PD) study of sordarin derivatives in a lethal C. albicans infection in mice, abstr. J-74 Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998 472 American Society for Microbiology Washington, D.C
  4. 4.↵
    1. Capa L.,
    2. Mendoza A.,
    3. Lavandera J. L.,
    4. Gómez de las Heras F.,
    5. Garcı́a-Bustos J. F.
    Translation elongation factor 2 is part of the target for a new family of antifungals. Antimicrob. Agents Chemother. 42 1998 2694 2699
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Domı́nguez J. M.,
    2. Kelly V. A.,
    3. Kinsman O. S.,
    4. Marriott M. S.,
    5. Gómez de las Heras F.,
    6. Martı́n J. J.
    Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob. Agents Chemother. 42 1998 2274 2278
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Domı́nguez J. M.,
    2. Martı́n J. J.
    Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans. Antimicrob. Agents Chemother. 42 1998 2279 2283
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Gomez M. G.,
    2. Garcia Bustos J. F.
    Ribosomal P-protein stalk function is targeted by sodarin antifungals. J. Biol. Chem. 273 1998 25041 25044
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Herreros E.,
    2. Martinez C. M.,
    3. Almela M. J.,
    4. Marriott M. S.,
    5. Gomez de las Heras F.,
    6. Gargallo-Viola D.
    Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi. Antimicrob. Agents Chemother. 42 1998 2863 2869
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Johnson P. C.,
    2. Khardori N.,
    3. Najjar A. F.,
    4. Butt F.,
    5. Mansell P. W. A.,
    6. Sarosi G. A.
    Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am. J. Med. 85 1988 152 158
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. McKinsey D. S.,
    2. Gupta M. R.,
    3. Driks M. R.,
    4. Smith D. L.,
    5. O’Connor M.
    Histoplasmosis in patients with AIDS: efficacy of maintenance amphotericin B therapy. Am. J. Med. 92 1992 225 227
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    National Committee for Clinical Laboratory Standards Reference method for broth dilution antifungal susceptibility testing for yeasts: approved standard M27-A. 1997 National Committee for Clinical Laboratory Standards Wayne, Pa
  12. 12.↵
    1. Wheat J.
    Histoplasmosis: recognition and treatment. Clin. Infect. Dis. 19 (Suppl. 1) 1994 S19 S27
    OpenUrl
  13. 13.↵
    1. Wheat J.,
    2. Hafner R.,
    3. Korzun A. H.,
    4. Limjoco M. T.,
    5. Spencer P.,
    6. Larsen R. A.,
    7. Hecht F. M.,
    8. Powderly W.,
    9. AIDS Clinical Trial Group
    Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am. J. Med. 98 1995 336 342
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Wheat L. J.
    Histoplasmosis in Indianapolis. Clin. Infect. Dis. 14 (Suppl. 1) 1992 S591 S599
    OpenUrl
  15. 15.↵
    1. Wheat L. J.,
    2. Hafner R.,
    3. Wulfsohn M.,
    4. Spencer P.,
    5. Squires K.,
    6. Powderly W.,
    7. Wong B.,
    8. Rinaldi M. G.,
    9. Saag M.,
    10. Hamill R.,
    11. Murphy R.,
    12. Connolly-Springfield P. A.,
    13. Briggs N.,
    14. Owens S.,
    15. NIAID Clinical Trials and Mycoses Study Group
    Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 118 1993 610 616
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Wheat L. J.,
    2. Slama T. G.,
    3. Zeckel M. L.
    Histoplasmosis in the acquired immune deficiency syndrome. Am. J. Med. 78 1985 203 210
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Zamarro M. T.,
    2. Martin J. J.,
    3. Dominguez J. M.
    Sordarins inhibit Aspergillus fumigatus protein synthesis, abstr. J-83 Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998 474 American Society for Microbiology Washington, D.C
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Activities of Sordarins in Murine Histoplasmosis
John R. Graybill, Laura Najvar, Annette Fothergill, Rosie Bocanegra, Federico Gomez de las Heras
Antimicrobial Agents and Chemotherapy Jul 1999, 43 (7) 1716-1718; DOI: 10.1128/AAC.43.7.1716

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Activities of Sordarins in Murine Histoplasmosis
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Activities of Sordarins in Murine Histoplasmosis
John R. Graybill, Laura Najvar, Annette Fothergill, Rosie Bocanegra, Federico Gomez de las Heras
Antimicrobial Agents and Chemotherapy Jul 1999, 43 (7) 1716-1718; DOI: 10.1128/AAC.43.7.1716
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENT
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

antifungal agents
Histoplasmosis

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596